Retatrutide, tirzepatide and Ozempic: understanding the names

Start with molecule, brand and status

Retatrutide and tirzepatide are molecule names. Ozempic is a brand containing semaglutide. “Reta” and “tirz” are informal abbreviations; GLP-1 names a hormone and receptor pathway. These terms sit at different levels, which is why a simple three-name ranking is confusing.

Tirzepatide is used in the US brands Mounjaro and Zepbound. Semaglutide is used in Ozempic and Wegovy. Retatrutide remains investigational, according to Lilly’s October 2026 status explanation; it is not an approved consumer medicine.

What the receptor names tell you

Receptors are part of how a cell receives a signal. An agonist activates a receptor. GLP-1 and GIP are involved in the body’s response to food; glucagon is another hormone signal involved in glucose regulation. A medicine can be designed to act at one or several of these receptors.

The labels identify semaglutide’s GLP-1 action and tirzepatide’s dual GIP/GLP-1 action. Retatrutide’s investigational molecule activates three targets. Counting targets does not establish a treatment’s suitability or compare its safety with another medicine. Those questions require the specific clinical and regulatory evidence.

“GLP-3” is sometimes used as an informal nickname for a triple agonist, but Lilly notes that it is not the scientific class name. Saying which receptors are targeted is clearer. Our illustrated GLP history explains how hormone research reached today’s different molecules.

A brand name still needs a presentation

Two brands can contain the same molecule and have different labels. The current Ozempic labels concern specified type 2 diabetes populations and related outcomes; Wegovy has product-specific weight-management and other indications. Mounjaro and Zepbound both contain tirzepatide, but their labeled uses differ. The age groups and clinical conditions in the exact indication matter.

Current information also differs from older summaries. Ozempic is no longer accurately described as injection-only in US labeling: a January 2026 tablet prescribing document covers oral semaglutide under the Ozempic and Rybelsus names. The current Wegovy label includes tablets as well as injection, with different indication details.

A practical way to read a medicine document is to write down four things: brand, active ingredient, presentation and label revision. Then find the section relevant to the question. The storage instructions for a pen, a vial and a tablet package cannot be assumed from a broad molecule name.

Ask what kind of evidence a headline describes

A prescribing label reports authorized uses and instructions. A clinical-trial paper reports what happened under a study’s defined conditions. A sponsor’s topline announcement can summarize new results before a full paper is available. A trial registry or enrollment update can describe a study without supplying results.

For a useful first pass, identify the population, comparator, duration and endpoint. A study in adults with type 2 diabetes can answer a different question from a study in obesity without diabetes. A comparison against placebo is different from a direct comparison against another medicine. A reported weight percentage, an A1C percentage-point change and kilograms are different units.

Retatrutide research therefore belongs alongside an explicit investigational-status statement. A promising result does not itself create regulatory approval, and an enrollment milestone does not answer which intervention performed better. The current label and the actual study question should travel with the result.

Turn the terminology into a useful conversation

If you are trying to understand an existing prescription, begin with the exact name on your package rather than an online abbreviation. Ask which indication applies, which presentation you have and where its current Medication Guide is. If a headline prompted the question, take its link and ask whether the people and products in that study match the situation being discussed.

The official labels include important warnings, contraindications and interactions. A naming map cannot determine an individual’s treatment choice. It can make the conversation clearer and help you find the correct source without mixing a brand, a molecule and a research candidate.

For everyday organization rather than medicine comparisons, see the practical starter-kit guide and the travel-case worksheet.

Explore the deeper comparisons

• Tirzepatide vs semaglutide: what the direct trial tested
• Retatrutide vs tirzepatide: approval status and the evidence gap
• Ozempic vs Wegovy: same molecule, different labels
• Mounjaro vs Zepbound: understanding the tirzepatide brands
• Oral vs injectable GLP treatments: compare the routine
• Retatrutide vs semaglutide: what the new diabetes trial reports